

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Prostate cancer	Na <sup>+</sup> /K <sup>+</sup> ATPase pump; src	<p>Mouse and cell culture studies suggest inhibiting src signaling with an Na<sup>+</sup>/K<sup>+</sup> ATPase-derived peptide could help treat prostate cancer. In three human prostate cancer cell lines, the Na<sup>+</sup>/K<sup>+</sup> ATPase-derived peptide (pNaKtide) inhibited proliferation compared with a control peptide. In a mouse model of human prostate cancer, pNaKtide lowered tumor growth and volume compared with vehicle. Next steps could include designing an optimized version of pNaKtide and evaluating it in mouse models of prostate cancer. Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. market the dual BCR-ABL tyrosine kinase and src inhibitor Sprycel for acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML). The compound is in Phase III testing to treat prostate cancer. Bosutinib, a dual BCR-ABL tyrosine kinase and src inhibitor from Pfizer Inc., is in Phase III testing for CML and Phase II testing for breast cancer.</p> <p>At least three other companies have src inhibitors in Phase I trials or earlier to treat prostate cancer.</p> <p><b>SciBX 4(32); doi:10.1038/scibx.2011.906</b>  <b>Published online Aug. 18, 2011</b></p>	Patent and licensing status unavailable	<p>Li, Z. <i>et al. J. Exp. Med.</i>; published online July 22, 2011; doi:10.1074/jbc.M110.207597</p> <p><b>Contact:</b> Zijian Xie, The University of Toledo Health Science Campus, Toledo, Ohio            e-mail:  <a href="mailto:zi-jian.xie@utoledo.edu">zi-jian.xie@utoledo.edu</a></p>